Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. These Companies have major upcoming catalysts such as an impending FDA approval, drug launch,data...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company, is developing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, an approach that has the potential to address the unmet needs in cardiovascular, metabolic and fatty liver diseases. The Company’s research is...
Sierra Oncology, Inc. (NASDAQ: SRRA) is focussed on creating novel targeted therapies that address large unmet needs in rare forms of cancer. The Company’s lead product candidate is momelotinib, a selective and orally bioavailable JAK1, JAK2 and ACVR1/ALK2 inhibitor being developed for the treatment of...
Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650 deaths every year as per an estimate by the American Cancer Society, these numbers are steadily rising over the years with approximately 99,780 new melanomas diagnosis being made each year. The...
Adicet Bio, Inc. (NASDAQ: ACET) is a biotechnology Company working on bringing allogeneic gamma delta T cell therapies for cancer and other therapies. The Company had merged with resTORbio, Inc. to create a combined entity, in September 2020. We take a look at the Company’s...
Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company developing novel first-in-class antibody therapeutics targeting oncology and infectious diseases, announced the receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) for its recently submitted Investigational New Drug (IND) for IMM-BCP-01, a three-antibody...
Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. The Companies we have shortlisted this week have entered into strategic collaborations with some...
Allakos, Inc. (NASDAQ: ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial. The studies were evaluating the Company’s...
Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. Our biotech picks that are making strides in fields such as Hepatitis B, rare...
Fennec Pharmaceuticals (NASDAQ: FENC), a specialty pharmaceutical company, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for PEDMARK™ (sodium thiosulfate), which was being developed as an intravenous administration for the prevention of ototoxicity...
